Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
Being able to 3D print human organs for transplant is game changing, being able to 3D print them directly into patients is sci-fi realised.
So far in the past few years I’ve talked a lot about how we are now using exponential technologies like 3D printing, 3D Bio-Printing, and 4D Bio-Printing to print human organs and tissues on demand in hospitals and labs. But what if you didn’t have to bother with printing them in a lab and could just print them straight into the transplant patients who need them? Well, now in another medical advance that future might one day become a possibility.
Although we’re hearing more about 3D printed human organs and tissues the fact remains that they still need to be implanted into patients using relatively large incisions, but now a new bio-ink could allow body parts to be printed directly within the body.
First of all, other types of bio-inks do already exist. They’re generally a liquid containing living cells, a framework material, and growth factors that prompt the cells to reproduce within that framework material, gradually changing it over to pure biological tissue.
Such bio-inks are extruded from the nozzle of a 3D printer, building up body parts outside of the body, layer by layer. In many cases, they’re cured into a solid material via exposure to ultraviolet light. Unfortunately, though, UV rays would be harmful to the patient’s own tissue if administered inside the body.
That’s where the new bio-ink comes in. It was developed through a collaboration between scientists from the California-based Teraski Institute, Ohio State University, and Pennsylvania State University.
The fluid is dispensed from the fine tip of a robotically-controlled nozzle, that is surgically inserted into the patient’s body through a small incision. In order to hold each strand of the bio-ink in place, the nozzle punctures a small void in the patient’s soft internal tissue, then deposits an anchoring blob of the fluid within that space. As the nozzle is subsequently withdrawn, it places another blob on the outside of that tissue, serving as an additional anchor. The rest of the strand is then drawn over to another anchoring point.
Importantly, the bio-ink can be internally applied at normal body temperature, and cured into a solid using a non-UV visible light source, and that’s the potential game changer.
Although the substance may someday be used to build parts such as blood vessels or spinal discs, like the ones that were printed outside of the body recently, in vivo it’s hoped that some of its more immediate uses may include the application of patches on damaged or defective organs, such as to replace damaged heart tissue after a heart attack, or the creation of hernia repair meshes and much more. The research is described in a paper that was recently published in the journal Biofabrication.
Source: Teraski Institute